Abdul Mannan: Why Apixaban May Be the Safer Choice for Acute VTE
Abdul Mannan, Consultant Hematologist at Betsi Cadwaladr University Health Board, shared a post on LinkedIn:
“For years, we’ve been prescribing both apixaban and rivaroxaban for acute VTE as if they were identical twins.
They’re not.
The COBRRA trial just published in NEJM (Castellucci LA et al., 2026) is the first randomised head-to-head comparison of these two DOACs in acute symptomatic VTE.
And the results are clear.
Here’s what the data shows:
- Clinically Relevant Bleeding: 3.3 percent with apixaban versus 7.1 percent with rivaroxaban
- Major Bleeding: 0.4 percent versus 2.4 percent (RR 0.16 – that is not a small difference)
- Recurrent VTE: 1.1 percent versus 1.0 percent (no meaningful difference)
Same protection. Less bleeding. That’s a win for patients.
This was a pragmatic, open-label, blinded-endpoint trial with 1:1 allocation across acute proximal DVT and PE.
Real-world design. Blinded outcome adjudication. Three months follow-up.
The limitation worth noting: it excluded active cancer, pregnancy, severe renal impairment, and extreme body weight.
So this applies to your standard acute VTE patient, not every patient.
But for that standard patient?
The choice just got easier.
Apixaban appears to be the safer DOAC for acute VTE treatment when bleeding risk matters. And bleeding risk always matters.
Does this change your practice?
Are you already defaulting to apixaban, or does your institution still treat them as equivalent?
Drop your thoughts below.”
Other posts featuring Abdul Mannan on Hemostasis Today.
-
Sep 25, 2026, 09:49Haley Coleman: Volunteering to Support Hemophilia Awareness
-
Sep 25, 2026, 08:55Hitarth Mehta: BHMS Students Gain Practical Exposure to Haemophilia Diagnosis
-
Sep 25, 2026, 07:25Varun Capoor: How Therapeutic Apheresis and Transfusion Medicine Can Complement Clinical Management in SCD
-
Sep 25, 2026, 07:14Manshi Kesharwani: SAK-GQDs Modulate Thrombus Burden and Endothelial Function in Deep Vein Thrombosis
-
Sep 25, 2026, 06:20Farjah Hassan Algahtani: How Can We Better Identify Patients at Risk of Blood Clots after Metabolic and Bariatric Surgery?
-
Sep 25, 2026, 05:59Carla Lewis: Kids Conquering Sickle Disease Joins Nemours Children’s Hospital for 2nd Annual Awareness Event
-
Sep 25, 2026, 05:47Omid Seidizadeh: Evolutionary Constraint and Population Variation Across Coagulation Genes
-
Sep 25, 2026, 05:40Gerald Bertrand: Presenting UMi-NGS Non-Invasive Foetal HPA Genotyping at DGTI 2026
-
Sep 25, 2026, 05:33Urge Congress to support the Sickle Cell Disease Comprehensive Care Act – ASH